In Advanced Prostate Cancer, Statin Use With Androgen Ablation Ups Survival
Statin users receiving androgen ablative therapies had a 35% reduced risk of death from advanced prostate cancer.
Prostate Cancer News
PROSTATE CANCER ADVISOR
Prostate Cancer News
Racial Disparities in Radiotherapy Regimens for Prostate and Breast Cancer
Black cancer patients are less likely than their White counterparts to receive shorter radiotherapy regimens, a study suggests.
Serial SBRT Potentially Beneficial in Oligometastatic Prostate Cancer
Serial stereotactic body radiation therapy directed by PET using novel radiotracers may offer clinical benefits in patients with oligometastatic prostate cancer.
Enzalutamide, Abiraterone Compared for mCRPC With Comorbidities
Patients with comorbidities are not routinely included in clinical trials.
Melanoma Diagnosis Linked to Increased Risk of Prostate Cancer
A more than 2-fold increased risk of prostate cancer was seen for patients whose first melanoma diagnosis was 10 to 15 years before study recruitment.
Accredited Hospitals Fail to Disclose Costs of Common Cancer Surgeries
Roughly half of hospitals accredited by the ACS-CoC failed to disclose the cost of 5 common cancer surgeries, researchers found.
Medicine vs Food: The Patient Care Dilemma of Financial Toxicity
Physicians are calling on colleagues to bring up the cost of care and its potential impact when discussing treatment options with patients.
Metastasis-Directed Therapy Alone May Treat Solitary Prostate Cancer Recurrence
This is the first study to assess the role of metastasis-directed therapy in solitary metastatic oligorecurrent prostate cancer in the absence of systemic therapy.
18F-NaF PET-CT More Accurate Than 99mTc-MDP SPECT for Detecting Bone Metastasis
Results of a phase 3 trial suggest 18F-NaF PET-CT is more effective than 99mTc-MDP SPECT for detecting bone metastasis in patients with breast or prostate cancer.
YouTube, TikTok Videos Don’t Provide Quality Information on Prostate Cancer Screening
None of the YouTube or TikTok videos analyzed contained both high-quality and accurate information on prostate cancer screening.
Overall Cancer Mortality 18% Higher in American Indians/Alaska Natives
Breast and prostate cancer mortality rates were higher in AIAN individuals than in White individuals, despite lower incidence rates.
Long-Term Data Support HFRT as Standard Care in High-Risk Prostate Cancer
Hypofractionated radiotherapy produces similar long-term outcomes as conventionally fractionated radiotherapy in high-risk prostate cancer, a phase 3 study suggests.
Radiotherapy of Asymptomatic Bone Metastases Reduces Skeletal-Related Events
Prophylactic radiotherapy of asymptomatic bone metastases can reduce skeletal-related events and improve survival in patients with solid tumors, a study suggests.
Most Doctors Surveyed Said Life Expectancy Should Guide Cancer Screening
About 75% of physicians surveyed agreed that a life expectancy of fewer than 10 years is a reasonable criterion for stopping cancer screening.
Concurrent/Adjuvant ADT “Should Be Standard” With PORT for Localized Prostate Cancer
Concurrent/adjuvant ADT was associated with improved metastasis-free survival, distant metastasis, prostate cancer-specific mortality, and overall survival.
Cediranib Improves rPFS in Metastatic Castration-Resistant Prostate Cancer
Adding cediranib to olaparib more than doubled the median radiographic progression-free survival.
Continued Enzalutamide Can Delay Progression in mCRPC Despite Resistance
Continuation of enzalutamide in combination with docetaxel and ADT delayed progression in patients with metastatic castration-resistant prostate cancer whose disease previously progressed on enzalutamide.
Proton FLASH Radiotherapy Deemed Feasible, Comparable to Conventional Dose Rate Radiotherapy
Proton FLASH radiotherapy is feasible, safe, and provides pain relief for cancer patients with bone metastases, according to a first-in-human trial.
Undetectable PSA Levels Tied to Improvements in rPFS, OS in Metastatic Hormone-Sensitive Prostate Cancer
Patients with mHSPC who receive enzalutamide plus ADT are 4 times more likely to achieve undetectable PSA levels than patients who receive ADT alone, according to an analysis of data from the ARCHES trial.
Robotic Prostate Cancer Surgery Tied to Financial Harm in Younger Patients
Younger patients have a higher risk of financial toxicity following robotic prostate cancer surgery, a study suggests.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...